Company intelligence / Profile preview
Elpiscience
Suzhou, Jiangsu, Chinaelpiscience.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Elpiscience has a robust pipeline of more than ten innovative molecules focused on cancer immunotherapy and autoimmune diseases. Its leading assets, ES101 and ES102, are both in Phase I clinical trials. Three additional first-in-class candidates are currently undergoing IND-enabling studies. The company leverages proprietary antibody discovery technologies to address unmet needs in oncology and autoimmunity.[1][2][3]
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)Other biologics (immunotherapies)
- Industry
- Biotech
02
Drug pipeline
16 assets15 more assets in the full pipeline.
03
Partnerships
Global strategic partnerships mentioned but specific partners not named publicly as of current data[2].
Beyond the preview
Go deeper on Elpiscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Elpiscience.